NASDAQ:ZBIO

Zenas BioPharma Q2 2025 Earnings Results & Report

Zenas BioPharma logo
$23.85 -1.19 (-4.75%)
Closing price 04:00 PM Eastern
Extended Trading
$23.85 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma missed analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$1.25 versus the -$1.02 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Zenas BioPharma EPS Results

Actual EPS
-$1.25
Consensus EPS
-$1.02
Beat/Miss
Missed by -$0.23
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 7 quarters

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$5 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zenas BioPharma Q2 2025 Earnings FAQ

Zenas BioPharma (NASDAQ:ZBIO) reported earnings of -$1.25 per share for Q2 2025, missing the consensus estimate of -$1.02. The report was announced on Tuesday, August 12, 2025.

Zenas BioPharma Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
FY2026 EPS Forecast for Zenas BioPharma Decreased by Analyst
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business.

Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.

The company is led by co-founder and Chief Executive Officer Hua Mu, who has experience in the biopharmaceutical industry. Zenas’s development efforts are aimed at patients with immune-mediated diseases for which existing treatment options may be limited.

View Zenas BioPharma Profile